¤E¤Q¤T¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¤ßŦ¬ì

(B) 1.¯f¤H¨k©Ê68·³¡A¦]¥ý¦³«æ©Ê¯Ýµh¡A«áµo§@»´«×©I§l§xÃø¡A¸g¹L28¤p®É«á¡A¤~´MÂå¦í°|ªvÀø¡C²z¾ÇÀˬdµo²{«æ¯fª¬¡A¦åÀ£108/74 mmHg¡B¤ß¸õ108 /min¡B¤£³W«h¡BÀVÀR¯ß«ã±i¡B¤ßŦÂX¤j¡B¦³S3¡B¤ß¦y³¡¦³Gr.II/VI¤ßÁY©Ê¤ßŦÂø­µ¡A¥ª«á¯Ý¤U³¡¦³ÀãÅo­µ¤Î¸}³¡¤ô¸~¡A¤ß¹q¹Ï§e²{¨å«¬«e¾À¤ß¦Ù±ð¶ëÅܤơC¨Ì¾Ú¹êÃÒÂå¾Ç­þ¨ÇÃĪ«¾A¦X¥»¯f¤HªA¥Î¡Ha.ÀR¯ßª`®gtPA¡A¥ýµ¹¤©©Ó¸ü¡]loading¡^¾¯¶q15 mg¡A«e¥b¤p®É50 mg¡AÀH«á¤@¤p®É35 mgb. Aspirin 80 mg QDc. Metoprolol 50 mg QDd. Captopril 12.5 mg BIDe. Nifedipine 10 mg TID
A.a+b+c
B.b+c+d
C.c+d+e
D.a+c
E.b+d
 
(C) 2.¨å«¬ªºÄY­«¥D°Ê¯ß佤³¬Âꤣ¥þ(Aortic valvular regurgitation)Å¥¶E¤£¥]¬A:
A.A high -pitched, blowing, decrescendo diastolic murmur at left lower sternal border
B.A mid-diastolic rumbling murmur at apex
C.An open snap
D.A systolic ejection murmur
E.An S4 gallop
 
(D) 3.ÂX¤j¤ß¦Ù¯f(Dilated cardiomyopathy)¬OºØ«ùÄò´c¤Æ¯fµ{ªº¤ßŦ¯f¡A±`¦³¦å®ê®ê¶ë¡B¤ß«ß¤£¾ã¤ÎÖ`¦ºªºµo¥Í¡C¦³Ãöªº¦X²zÁ{§É³B¸m¦³¡Ga.±o¨Ï¥Î§Q§¿¾¯¡BACE inhibitors¡B£]-adrenergic blockers¤Îdigoxinb.À³¨Ï¥Î§Ü¤£¾ã¯ßÃĪ«¹w¨¾¤ß«ß¤£¾ã¤§µo¥Íc.À³§Ù°s¤ÎµÒd.©Ò¦³¯f¤HÀ³¦³¤ß¦Ù¤Á¤ù½T©w¶EÂ_¥H¬°¥ÎÃĤ§°Ñ¦Òe.¤ßŦ²¾´Ó¬O°ß¤@ªº¿ï¾Ü¡C
A.a+b+c
B.b+c+d
C.c+d+e
D.a+c
E.b+d
 
(C) 4.¯f¤H¬O38·³¤¤¾Ç¤k©Ê¦Ñ®v¡A¨â¦~«e¶}©l¹B°Ê©Ê©I§l§xÃø¡A·í®É¦³²Ä¤G­LÃh¥¥¦b¨­¡A¥Í²£«á¨Ã¥¼¦³§ïµ½¡A¤Ï¦Ó³vº¥¥[­«¡A³Ìªñ¼Æ¶g¥u­n¤W¼Ó±è¤@¼h´N®ð«P¬Æ«æ¡A¤]¶¡©Î¦³©ü³Öªºµo¥Í¡A¤D¦í°|¶EÀø¡C²z¾ÇÀˬd¡G¦åÀ£140/95 mmHg¡BT/P/R¡G36.5¢J/84/20¡FÀVÀR¯ß¥¼¨£«ã±i¡F¤ß«ß³W«h¡B¥iIJı¥k¤ß«ÇÂX¤j¡B¦b¥ª¤U¯Ý½t¦³GrII/IV systolic murmur¡BS1¥¿±`¡BP2¥[­«¡B¥¼¦³S3¤ÎS4¡A¥¼¦³¨x¸~¤Î¸}¤ô¸~¡BªSª¬«ü(clubbing fingers)©ÎµoÖæ¡C¯Ý³¡X¥ú¦p¹Ï4 ¤Î¤ß¹q¹Ï ¦p¹Ï¥Ü¡C³o¦ì¯f¤H³Ì¥¿½Tªº¤ßŦ¶EÂ_¬O
A.Postpartum cardiomyopathy
B. Mitral stenosis
C. Pulmonary arterial hypertension
D. Aortic valvular stenosis
E. Obstructive hypertrophic cardiomyopathy
 
(D) 5. ©Ó¤WÃD¡A¥»¯f¨Ò¤§¶EÂ_®Ú¾Ú¦b©ó¡Ga.¯fª¬»PÃh¥¥¯f¥v¦³Ãöb.¥ª¤ß«ÇªÎ«pc.¥k¤ßÂX¤jd.¥ª¤ßŦ°IºÜe. °ª¦åÀ£
A. a+b+c
B. b+c+d
C. c+d+e
D. a+c
E. b+d
 
(B) 6.¤U¦C¦óªÌ¬O¤£¥¿½TªºÃöÁp
A.Ebstein·î§Î-¥k¤ß«ÇÂX¤j
B.Lutembacher's¯g­Ô¸s-¥ª¤ß«ÇÂX¤j
C.Fallot¤ó¥|¦X¯g-ªÍ°Ê¯ß°ª¦åÀ£
D.Sinus Valsalva¯}µõ-«ùÄò©Ê¤ßŦÂø­µ
E.Marfan¯g­Ô¸s-¥D°Ê¯ßÄuÂX¤j
 
(C) 7. ¯f¤H26·³¡A¨k©Ê¡A©yÄõÀY«°¤u¤H¡A¥D¶D°¸¦³¯Ý´e¾ú¸g¤@­Ó¤ë¡A¥L¦Û¤p¶}©l´N¤£¾A¹B°Ê¡A¯Ý¤f®É¦³ÄÁÂ\¼@°Ê¡A³Ìªñ±`¦³¹B°Ê¬ÛÃöªº¯Ý´e¡A ¦ñ¦³¤ß±ª·w¯t¡A¦³®É±j«×¹B°Ê·|¦³µoÖæ¡C¬J©¹¯f¥v¥¼¦³¯S§O¡C²z¾ÇÀˬd¡G¨­°ª155cm¡BÅé­«45.5kg¡B¦åÀ£108/70mmHg¡B¤ß¸õ80/min¡BÀVÀR¯ß¥¿±`¡BPMI¥ª5th ICS(intercostal space)ªºLMCL(left middle clavicular line)¡BRV heave¡B¦b¥ª¤W¯Ý½t¦³Gr. III/VI systolic ejection murmur with fixed splitting S2¡A¥¼¦³¤ßÂø­µ¶Ç²¾¡AP2¥[­«¡C¨ä¥L²z¾ÇÀˬd¥¼¦³¤£¥¿±`¡A¯Ý³¡X¥ú¦p ¹Ï7¡A ¤ß¹q¹Ï¦p¹Ï¡C¥»¯f¤H°µ¥¿½Tªº¤ßŦ¶EÂ_¬O¡G
A. Pulmonary stenosis
B. Idiopathic pulmonary hypertension
C. Atrial septal defect
D. Aortic stenosis
E. Mitral stenosis
 
(C) 8. ¯f¤H53·³¡A¨k©Ê¡A¦]¦³¤@­Ó¤ëªº¯Ý´e¨ìªù¶E¨Dªv¡A¯Ý´e·|¦³¥ª¤U¤Úµo³Â¡A»P¹B°Ê¬ÛÃö¡A¨C¦¸µo§@3¦Ü5¤ÀÄÁ¡A¥ð®§¥i½w¸Ñ¡C¯f¥v¥]¬A°ª¯×¦å¥b¦~¤Î ©â·Ï30¦~¡A¦ý¤w§ÙµÒ¡C²z¾ÇÀˬd¡G¦åÀ£145/96mmHg¡B¤ß¸õ80/min¡B¨ä¥LÀˬd©|µL¤£¥¿±`¡C¤ß¹q¹Ï¦p¹Ï 8-1¡B 8-2¡A ¥Í¤Æ¡Gsugar(AC/PC)95/141 mg/dl¡Btotal cholesterol 191 mg/dl¡BHDL-C 29 mg/dl¡BLDL-C 104 mg/dl¡Btriglyceride 289 mg/dl¡BAST 27U/L¡BALT 45 U/L¡B creatinine 1.2 mg/dl¡Buric acid 9.2 mg/dl¡C«ö·Ó¹êÃÒÂå¾Ç¤Î§Ú°ê°·«O¤§³W©w¡A¤U¦C¦óªÌ³B¸m¬O¥¿½Tªº
A. ¥»¯f¤HÀ³µ¹¤©«DÃĪ«ªvÀø(¶¼­¹¡B¹B°Ê¡B§ÙµÒ°sµ¥¥Í¬¡ÁB¥¿)¤T¦Ü¤»­Ó¤ë¡A¤~¥i¨Ï¥Îfenofibrate (Lipanthyl)100 mg QD
B. ­°¦å¯×ÃĪ«ªºªvÀø¥Ø¼Ð¦btriglyceride < 200 mg/dl¡Bcholesterol < 160 mg/dl
C. ¥i§Y¨è°_¨BªvÀø°ª¦åÀ£¨Ã³]©wsystolic¤Îdiastolic BPªvÀø¥Ø¼Ð¤À§O¦b<140 mmHg ¤Î90 mmHg
D. ¨Ì§Ú°ê°·«O³W©w¡A³o¦ì¯f¤Hªº­°¦åÀ£¥H³æ¤èªvÀø(monotherapy)¬°©y
E. ¨Ì¬ü°êJNC-7¡A¥»¯f¤H³Ì¦X¾Aªº°_¨BªvÀø¬O£\-adrenergic receptor blocker
 
(A) 9. ¯f¤H69·³¨k©Ê¡A¤T¤Ñ«e¦³¥b¤p®É¯Ýµh¡A»P¹B°ÊµLÃö¡AÀH«á¦³Âù°¼¤ô¸~¡A¤£¦A¦³¯Ýµh¡A¤D¨ìªù¶E¨DÂå¡A«áÂà°e«æ¶E¦¬ªv¡C¯f¥v¦³¿}§¿¯f6-7¦~¥~¡A µL¨ä¥L¦MÀI¦]¯À¡C²z¾Ç¡G¦åÀ£139/79mmHg¡B¤ß¸õ78/min¡B©I§l20/min¡C¥¼¦³ÀVÀR¯ß«ã±i¡AªÍ³¡¦³»´«×ÀãÅo­µ¡A¤ßŦ·LÂX¤j¡B¤ß¦y³¡¦³S4¤ÎGr II/VI systolic murmur¡B Âù¤p»L¤ô¸~¡A¨ä¥L¨ÃµL¤£¥¿±`¡C ¤ß¹q¹Ï ¦p¹Ï¡ACK/CKMB/TnI: 456 U/L/53. 1U/L/12.1U/L; sugar 153mg/dl¡Bcreatinin 2.5 mg/dl¡Btriglyceride 109 mg/dl¡Bcholesterol 145 mg/dl¡C¥»¯f¤H¤U¦C¦ó ªÌªº³B¸m¤£²Å¦X¹êÃÒÂå¾Ç¡G
A. ³w¥ÎtPA 15 mg ©Ó¸ü¾¯¶q(lodading dose)ÀRª`¡A45 mg/¥b¤p®É¤§ «á30 mg¤@¤p®É©MHeparin 3000uÀRª`¤Î10000u¦b500cc normal saline/24¤p®ÉÀRª`
B.Nitroglycerin 50 mg in 125 cc dextrose / salineÀR¯ßª`®g
C.ªA¥ÎGliquidone 30 mg BIDªvÀø¿}§¿¯f
D.¥X°|«e¸g¥Ö«aª¬°Ê¯ß¦¨§Î³N³B¸m
E.Aspirin 80 mg
 
(A) 10.¨S¦³¹êÃÒÂå¾Ç®Ú¾Ú¡A¤£«Øij¿ï¥Î¾ÉºÞ¿N¨`¤â³N(Catheter ablation)ªº¤ß«ß¤£¾ã¬°:
A.Ventricular tachycardia in patient with coronary artery disease
B.Idiopathic ventricular tachycardia with LBBB configuration and superior axis
C.Recurrent cavotricuspid isthmus atrial flutter
D.WPW syndrome with posteroseptal right atrium Kent tract
E.Atrioventricular nodal tachycardia
 
(C) 11.¤U¦C¦³Ãö¥D°Ê¯ß­éÂ÷(Aortic dissection)ªº»¡ªk¬O¤£¥¿½Tªº:
A.¥»¯f¬O¤T¯ÅÂåÀø³æ¦ìªº¤ßŦ«æ¯g
B.B«¬¥D°Ê¯ß­éÂ÷¦ñ¦³«æ©ÊµÇŦ°IºÜ¤´¥H¤º¬ìÀøªk¬°©y
C.¼h¤º¦å¶ô(Intramural hematoma)¥¼¦ñ¦³¥D°Ê¯ß¤º¼h(Intimal rupture)¯}µõ¡A¤£¦Ü©óµo¥Í¤ß¥]½¤¥R¶ñ¤Î§C¦åÀ£¤´¥H¤º¬ìªvÀø¬°©y
D.¤£«Ý¹q¸£Â_¼h¼v¹³¡A¥H­¹¹D¶W­µªi¶EÂ_²ÄI«¬¥D°Ê¯ß­éÂ÷´N¥i³w°e¥~¬ìªvÀø
E.¥HÀRª`labetalol 50 mg/10 min½Õ±±¦¬ÁYÀ£¦b100-120 mmHg¬O°_¨BªºªvÀø¥Ø¼Ð
 
(B) 12.¥H¤U°t¹ï¦óªÌ¬°¤£¥¿½T¡H
A.¯ß·i§¹¥þ¤£³W«h(irregularly irregular)¥B¨ä¤j¤p¤£¤@--¥ª¤ß©ÐÅÖºûŸ°Ê(atrial fibrillation)
B.ÂÛ¸õ¯ß(bounding pulse)--¦åÀ£130/82 mmHg
C.¯ß·i³W«h¦ý±j®z¤@¤j¤@¤p¥æ´ÀÅÜ°Ê--¥ª¤ß«Ç®g¥X²v(ejection fraction)20%
D.¥¿±`©I§lª¬ºA¤U¡A¦b§l®ð®É¯ß·i©úÅãÅÜ®z©Î®ø¥¢--¤ß¥]Ån¶ñ¶ë(cardiac tamponade)
E.¤ß³t²v¤j©ó¾ø°©°Ê¯ß(radial artery)¯ß·i³t²v--¯ß·iµu²Ò(pulse deficit)
 
(A) 13.¦³Ãö¤ßŦÂH²G½F(myxoma)¡A¤U¦C¦óªÌ¬°«D¡H
A.¤ßŦÂH²G½F¬°¤ßŦ³Ì±`¨£¤§­ìµo©Ê´c©Ê(¯f²z¤W)¸~½F
B.¯f¤H¥i¯à¥HªÍÆ{¦å¡A°Ê¯ß®ê¶ë¡Aµo¿N¡A©ü³Ö¡AÖ`¦ºµ¥ªí²{
C.¤ßŦť¶E¡AÂø­µ¥i¯à¦]Åé¦ì§ïÅܦӦ³©ÒÅܤÆ
D.¤ßŦ¶W­µªi¬°³Ì¦nªº¶EÂ_¤u¨ã
E.¶EÂ_«á¤@¯ë¤£°µ¾ÉºÞ¡AÀ³§Y®É¶}¤M
 
(D) 14.¦³Ãö«æ©Ê¥k¤ß«Ç¤ß¦Ù±ð¶ë¤§±Ô­z¡A¦bA-E¤§²Õ¦X¤¤¡A¦óªÌ¬°¥¿½T¡Ha.³q±`»P¤U¾À¤ß¦Ù±ð¶ë¦X¨Öµo¥Í¡A¤ß¹q¹Ï¤SÅã¥Ü¦bV3R©ÎV4R¾Éµ{¤§ST¬q¤W¤Éb.±`¦X¨Ö§C¦åÀ£¡A°ªÀVÀR¯ßÀ£¡A¦]¦¹À³»P¤ß¥]Ån¶ñ¶ë°µÅ²§O¶EÂ_c.³q±`ªÍ°Ê¯ß·¤À£³q±`¥¿±`©Îµy·L¤W¤Éd.ÀR¯ß¸É¥R²GÅé¥i´£°ª¦åÀ£e.µ¹¤©§Q§¿¾¯¤Îµv»ÄÆQ(nitrates)¥i§ïµ½¯f±¡
A.a+b+e
B.b+d+e
C.b+c+d
D.a+b+c+d
E.a+b+c+d+e
 
(E) 15.¹ï¥D°Ê¯ßäÄY­«¯U¯¶»Pªý¶ë©ÊªÎ«p©Ê¤ß¦Ù¯f¨âªÌ¤§±Ô­z¡A¦óªÌ¬°¤£¥¿½T
A.¨âªÌ¦³¬Û¦ü¤§Á{§Éªí²{¡A¥]¬A©I§l§xÃø¡A¯U¤ß¯g¡A©ü³Ö¤ÎÖ`¦º
B.¦b¥D°Ê¯ßäÄY­«¯U¯¶¡AÀV°Ê¯ß·i°ÊÅã¥Ü©µ¿ð¤W³»(slow upstroke)
C.¨âªÌ¤ß¹q¹Ï¬ÒÅã¥Ü¥ª¤ß«ÇªÎ¤j
D.¦bªý¶ë©ÊªÎ«p¤ß¦Ù¯f¡A¦¬ÁY´ÁÂø­µ¦b°µValsalva°Ê§@¤Î¯¸¥ß®ÉÅܤj¡AÃÛ¤U®ÉÅܤp
E.¦b¤ß°IºÜ®É¨âªÌ¬Ò¥i¨Ï¥ÎdigoxinªvÀø
 
(E) 16.¤@¦W35·³±w¦³¤G¦yä¯U¯¶¤§¤k©Ê¡A¦]ÄY­«©I§l§xÃø©ó«æ¶E«Ç¨D¶E¡A²z¾ÇÀˬdµo²{¯f¤HºÝ§¤©I§l¡A·NÃÑ©|ÄݲM´·¡A¤â¸}¦B§N¡A¦³µoÖæ²{¶H¡A¦åÀ£92/70mmHg¡A¤ß³t²v¨C¤ÀÄÁ160§¹¥þ¤£³W«h(irregularly irregular)¡A¤ßŦÀˬd¯Ý°©¥ª½t¦³¦¬ÁY´Á·i°_(parasternal lift)¡A²Ä¤@¤Î²Ä¤G¤ß­µ¤®¶i¡AÅ¥¤£¨ìÂø­µ¡AªÍ³¡¦³Äjº©©ÊÅo­µ¡A¤ß¹q¹ÏÅã¥Ü¤ß©ÐÅÖºûŸ°Ê(atrial fibrillation)¡A°£¤F¨Ñ»P®ñ®ð¥~¡A³Ì¾A·í¤§¥ß§Y³B¸m¬°
A.ÀR¯ßª`®gdigoxin
B.ÀR¯ßª`®gdopamine¤Î§Q§¿¾¯
C.ÀR¯ßª`®gverapamil
D.ÀR¯ßª`®gamiodarone
E.¹qÀ»(electrical cardioversion)
 
(B) 17. ¤WÃD¯f¤H¸g¤W­z³B¸m«á¡A¤ß¸õÅܬ°³W«h(³t²v¨C¤ÀÄÁ90)«á¡A©úÅãÅ¥¨ìopening snap¤ÎµÎ±i´ÁÂø­µ¡A¦åÀ£¦^¤É¦Ü112/78 mmHg¡AÀVÀR¯ßÀ£©úÅã¤W¤É ¬ù16 cm H2O¡AÀVÀR¯ßªiaªi¡A¸g¯Ý«e¤ßŦ¶W­µªiÀˬdÃÒ¹ê¯f¤H¦³ÄY­«¤G¦yä¯U¯¶¡A¥H§Q§¿¾¯ªvÀø«áªÍ¥R¦å(pulmonary venous congestion)§ïµ½¡A¸g­¹¹D¤ßŦ¶W­µªiÀˬd½T »{¥ª¤ß©Ð¤ºµL¦å®ê«á¬I¦æ®ð²y¾ÉºÞ¤G¦yäÂX±i³N¦¨¥\¡A¤U¦C±Ô­z¦óªÌ¬°«D¡H
A. ¤G¦yäÂX±i³N«e¤ß¾ÉºÞÀˬd¹w´Á©Ò¨£¬°¥k¤ß©Ð¡AªÍ°Ê¯ß·¤À£(wedge pressure)²§±`¤W¤É
B. ³N«áA2-opening snap¶¡¹jÅܵu
C. µÎ±i´ÁÂø­µÅܵu©Î®ø¥¢
D. ²Ä¤@¤ß­µ¤®¶i¤£ÅÜ
E.¥H¤W¬Ò¥¿½T
 
(C) 18. ¤@¦W60·³¤k©Ê¬°¿}§¿¯f¯f±w¡A¨ä°ª¦å¯×¯g¸g¤T­Ó¤ë«DÃĪ«ªvÀø«á¡AÁ`Áx©T¾J(TC)¬°198 mg/dl¡A§C±K«×¯×³J¥ÕÁx©T¾J(LDL-C)¬°110 mg/dl¡A °ª±K«×¯×³J¥ÕÁx©T¾J(HDL-C)¬°38 mg/dl¡A¤¤©Ê¯×ªÕtriglycerides(TG)¬°250 mg/dl¡A¥H¤U±Ô­z¦óªÌ¤£¥¿½T¡H
A. ¦¹¯f±wÁöµL«aª¬°Ê¯ß¯e¯f¤§¯gª¬(¦p¯U¤ß¯g¡A¤ß¦Ù±ð¶ë)¡A¦ýÀ³³Qµø¬°µ¥¦P¦³«aª¬°Ê¯ß¯e¯f(CAD equivalent)
B. ¦¹¯f±w²Å¦X°·«O­°¦å¯×¯gÃĪ«³W½d¡A¥iµ¹¤©§Ü¦å¯×ÃĪ«ªvÀø(À³¦P®Éµ¹¤©«DÃĪ«ªvÀø)
C. ¦p²Å¦X°·«O³W½d¡Astatin¡Afibrates¡Aniacin¤Îcholestyramineµ¥ÃĪ«¤¤¡A¦b¦¹¯f±w¤§­º¿ïÃĪ«¬°statin
D. ÃĪ«ªvÀø¥Ø¼Ð¬°Á`Áx©T¾JTC <160 mg/dl¡ALDL-C ¡Ø100 mg/dl¤ÎTG <150 mg/dl
E.(ªÅ¥Õ)
 
(D) 19.¤U¦C¥i¯à¾É­P§C¦åÀ£©Î¥ð§J¤§«æ¶E¤¤¡A¦óªÌ³Ì®e©ö¶EÂ_¤ÎªvÀø
A.§C®e©Ê¥ð§J(hypovolemic shock)
B.¤ß¥]Ån¶ñ¶ë(cardiac tamponade)¾É­P¤§ªý¶ë©Ê¥ð§J(obstructive shock)
C.ªÍ°Ê¯ß®ê¶ë(pulmonary embolism)¾É­P¤§ªý¶ë©Ê¥ð§J
D.±i¤O©Ê®ð¯Ý(tension pneumothorax)¾É­P¤§ªý¶ë©Ê¥ð§J
E.«æ©Ê¤ß¦Ù±ð¶ë¾É­P¤§¤ß¦]©Ê¥ð§J(cardiogenic shock)
 
(D) 20.¯Ý³¡X¥úÀˬd²§©ó¨ä¥L³¡¦ì¤§X¥úÀˬd¡A¥ç¥i¶¡±µµû¦ôªÍ´`Àô¨t²Î¦å¦æ°Ê¤O¾Ç(hemodynamics)¤§ª¬ºA¡A¤U¦C(a)-(d)¤§¦å¦æ°Ê¤O¾Ç©Ò¨£¤§A-E²Õ¦X¤¤¡A¨ä¥i¥¿½T¶¡±µµû¦ô(©w©Ê©Î¥b©w¶q)©Ò¨£¤§²Õ¦X¬°¦óªÌ(a)ªÍÀR¯ßÀ£¤ÎªÍ°Ê¯ß·¤À£(wedge pressure)(b)ªÍ°Ê¯ßÀ£(c)¥k¤ß«ÇµÎ±i´ÁÀ£(d)ªÍ¦å¬y¶q(¦p¦b¤ß©Ð¤¤¹j¯Ê·lµ¥¤ßŦ¥ª¥k¤À¬y¡Aleft - to- right shunt)
A.a+b
B.a+b+c
C.b+c
D.a+b+d
E.a+b+c+d
 
(B) 21.¤@¦W60·³¨k©Ê¡A¦]ÄY­«©I§l§xÃø¦Ü«æ¶E«Ç¨D¶E¡A²z¾ÇÀˬdµo²{¯f¤H¥bºÝ§¤©I§l¡A·NÃÑ©|²M´·¡A¦åÀ£100/70 mmHg¡A¤ß³t²v100/min³W«h¡A¤â¸}¦B§N¦Ó¦³»´·LµoÖæ²{¶H¦ýµL¯B¸~¡BÀVÀR¯ßÀ£¥¿±`¡B¤ßŦ¥ª¤ß«ÇÂX¤j¡B²Ä¤G¤ß­µ(P2)¤®¶i¡BµLÂø­µ¦ý¦³²Ä¥|¤ß­µ(S4)¡BªÍ³¡¦³Äjº©©ÊÅo­µ¡C¤ß¹q¹ÏÅã¥ÜÄu©Ð«ß(sinus rhythm)¤Î«D¯S²§©ÊSTTÅܤơA¯Ý³¡X¥ú¦³«æ©ÊªÍ¤ô¸~(pulmonary edema)¤Î¤ßŦÂX¤j¤§©Ò¨£¡A¤ßŦ¶W­µªiÀˬd¥ª¤ß«ÇÂX¤j¤Î¥ª¤ß«Ç®g¥X²v(ejection fraction)25%¡A¦¹¯f±w¸g¨Ï¥Îdopamine¡Bfurosemide¡Baldactone¡Bµv»ÄÆQ(nitrates)¡BACEI(angiotensin converting enzyme inhibitor)¤Î¤ò¦a¶ÀdigoxinªvÀø«áªÍ¤ô¸~©úÅã§ïµ½¡C¦b¦³Ãö¦¹¯f¤H¥i¨Ï¥Î¤§¤U¦CÃĪ«(a)-(d)¤§±Ô­z¡A¨äA-E²Õ¦X¡A¦óªÌ¬°¥¿½T¡H(a)¨Ï¥Îµv»ÄÆQ¡B¤ò¦a¶À¤Î§Q§¿¾¯¥i§ïµ½¦¹¯f¤Hªø´Á¹w«á(b)ACEI©ÎARB (angiotensin receptor blocker)¥i§ïµ½¦¹¯f¤Hªø´Á¹w«á(c)¨Ï¥Îaldactone¥i§ïµ½¦¹¯f¤Hªø´Á¹w«á(d)¨Ï¥Î¤A«¬¥æ·P¯«¸gªýÂ_¾¯(beta-blocker)¥i§ïµ½¦¹¯f¤Hªø´Á¹w«á¡A¦]¦¹·í¯f¤H­è¨ìÂå°|¯f±¡¥¼Ã­©w®É¡A§YÀ³¨Ï¥Î¦¹ÃÄ
A.a+c
B.b+c
C.b+d
D.a+b+c
E.a+b+c+d
 
(D) 22.±N¹ï°ª¦åÀ£¯f¤H¥HÃĪ«ªvÀø¡A¦p¦³¤U¦C¨ä¥¦¦X¨Ö¯g®É¡A¨ä­º¿ïÃĪ«»P¨ä¦X¨Ö¯g¤§¥H¤U°t¹ï¡A¦óªÌ¤£¾A·í¡H
A.¿}§¿¯fµÇ¯fÅÜ¡A³J¥Õ§¿--Âà¤ÆúC§í¨î¾¯(ACEI)©ÎARB(angiotensin receptor 1 blocker)
B.ÄáÅ@¸¢ªÎ¤j¡A±Æ§¿§xÃø--¥Ò«¬¥æ·P¯«¸g§í¨î¾¯(alpha-blocker)
C.¯U¤ß¯g--¤A«¬¥æ·P¯«¸gªýÂ_¾¯(beta-blocker)
D.¤ß©ÐŸ°Ê(atrial fibrillation)¡A¤ß«Ç³t²v¨C¤ÀÄÁ120--dihydropiridinesÃþ¶tÂ÷¤lªýÂ_¾¯(¦pnifedipine, amlodipine)
E.¥H¤W¬Ò¾A·í
 


< ¤E¤Q¤T¦~«×¸ÕÃD¥Ø¿ý >